GlassScriptPhysician profile
Michael Thomas Giordano
NPI 1154438349
$2,426.20
in general payments reported to CMS, 2019-2025
31 companies · $535 in 2025
The $535 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.73 · 2020: $25.63 · 2021: $191 · 2022: $258 · 2023: $643 · 2024: $759 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $551.66 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $288.52 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $232.31 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $138.69 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $134.72 | 2023-2025 | |
| Dexcom, INC. | $122.90 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $102.04 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $94.17 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $91.12 | 2022-2024 | |
| Exact Sciences Corporation | $80.69 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $55.53 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $47.19 | 2023 | Austedo Xr |
| Amarin Pharma, INC. | $45.02 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.08 | 2023 | Lifevest |
| Astellas Pharma US INC | $36.98 | 2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.68 | 2021-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $31.77 | 2024 | |
| Madrigal Pharmaceuticals | $30.13 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $29.36 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Medtronic, INC. | $28.52 | 2021-2025 | Abre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.41 | 2025 | Xifaxan |
| Eisai INC. | $28.11 | 2020-2022 | |
| Neurelis, INC. | $23.44 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $22.60 | 2023 | Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $18.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.11 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $14.86 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $14.71 | 2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2023 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giordano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.